17 results about "Psa antigen" patented technology

The invention relates to a construction method of an experimental autoimmune prostatitis rat model. The construction method comprises the following steps: S1, preparing a prostate specific antigen mixture; s2, selecting male SD rats as laboratory rats, and dividing the laboratory rats into a normal saline control group, a low-dose model group and a high-dose model group; s3, continuously injecting for 7 days, allowing the normal saline control group to accept injection of 0.2 ml of normal saline every day, allowing the low-dose model group to accept injection of 0.1 ml of prostate specific antigen mixture every day, and allowing the high-dose model group to accept injection of 0.2 ml of prostate specific antigen mixture every day; and S4, continuously feeding all groups of experimental mice to the 28th day, inducing the experimental mice in the low-dose model group and the high-dose model group by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and obtaining the experimental autoimmune prostatitis rat model. The use of animals can be reduced, the cost is reduced, and the modeling efficiency and stability can be improved.

A pro-moiety and a composition comprising a pro-moiety for use in a therapeutically or diagnostically effective amount in a method for detecting and / or treating prostate cancer in a subject is disclosed. The pro-moiety comprises a first peptide, and a second peptide that is linked to the first peptide, wherein the peptide comprises a sequence that is configured near a first terminus for conjugating to a drug to form a prodrug that is rapidly and / or highly selectively cleaved by prostate-specific antigen (PSA), and configured at a second terminus to bind with high selectivity to the active site of PSA, and the second peptide comprises a sequence having a negative charge to slow uptake of the prodrug by cells, and wherein the second peptide is cleaved from the first peptide upon proteolysis by PSA to produce a conjugate of the first peptide and the drug that is suitable for uptake by target cells.

The application discloses a fluorescent aptamer sensor and a method for detecting prostate specific antigen, wherein the fluorescent aptamer sensor comprises a solvent, and 5-carboxyltetramethylrhodamine labeled aptamer sequences and quencher PCN-223 dispersed in the solvent. The fluorescent aptamer sensor provided by the application has excellent selectivity and sensitivity in the detection of prostate specific antigen, and has a good application prospect.

The invention relates to the technical field of medical health data processing, and discloses a prostate cancer accurate diagnosis and treatment decision support system based on a knowledge graph, which comprises a multi-modal data acquisition module, a semantic alignment reasoning module and a decision link construction module, and is characterized in that prostate specific antigens, image scores, puncture grading and gene data are called by the system; a time phase difference between biochemical metabolism transient change and structure lag response is utilized to construct a multi-mode heterogeneous topological graph, a phase translation compensation representation vector is generated through a mapping operator, a decision link construction module determines node association weight, a deduction sub-graph reflecting disease evolution state is generated by utilizing path search, and the decision link construction module determines a decision link. According to the method, cross-modal time-phase deviation compensation logic is utilized, observation asynchronism is eliminated, early-stage small metastasis characteristics of tumors are captured, and the auditing performance of diagnosis and treatment decisions is improved.

The application relates to a method for constructing an experimental autoimmune prostatitis rat model, which comprises the following steps: S1, preparing a prostate specific antigen mixture; S2, selecting male SD rats as experimental rats and dividing the rats into a physiological saline control group, a low-dose model group and a high-dose model group; S3, continuously injecting for 7 days, wherein the physiological saline control group receives 0.2ml of physiological saline injection every day, the low-dose model group receives 0.1ml of the prostate specific antigen mixture injection every day, and the high-dose model group receives 0.2ml of the prostate specific antigen mixture injection every day; and S4, continuing to feed all the experimental rats in the groups until the 28th day, wherein the experimental rats in the low-dose model group and the high-dose model group are induced by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and an experimental autoimmune prostatitis rat model is obtained. The method can not only reduce the use of animals and the cost, but also improve the modeling efficiency and stability.

The present disclosure provides isolated peptides derived from prostate-specific antigen, peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treatment or prevention of prostate cancer. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treatment or prevention of prostate cancer.

The application discloses a sperm quality detection device and a preparation method thereof. The sperm quality detection device comprises a base material, a sperm activity detection module, an SP10 detection module and a PSA detection module. The sperm activity detection module comprises a containing cavity and a convex lens. The containing cavity has a detection plane. The convex lens is configured to be able to slide to a sample adding hole along with a sliding assembly and to magnify the image of the detection plane. The SP10 detection module comprises a P10 colloidal gold test strip. The PSA detection module comprises a PSA colloidal gold test strip. The application provides a detection device integrating sperm acrosome enzyme SP10 protein, prostate specific antigen PSA and special counting for a semen sample. The device is simple to operate and can provide a detection result in a short time. The detection result can be judged by the person to be detected independently, and the device is suitable for primary medical units and on-site rapid detection.

This invention discloses a PSA aptamer sensor based on a screen-printed electrode, its preparation, and detection method. In this invention, a composite material of AuNPs and graphene aerogel is used to modify the surface of a screen-printed electrode. The aptamer is modified onto the sensor by forming gold-sulfur (Au-S) bonds with a thiol-modified DNA single-stranded aptamer. Excess gold active sites are blocked with MCH to construct the PSA aptamer sensor. A certain concentration of PSA and UA is selected and incubated with the sensor. The EIS test method is used to detect PSA by recording its impedance changes, and the detection limit of the sensor is obtained. Utilizing the advantages of large-scale mass production and low cost of screen printing technology, combined with the excellent physical and electrical properties of nanomaterials, an electrochemical sensor for the detection of prostate-specific antigen (PSA) is prepared, enabling convenient, efficient, and low-cost detection, providing a new approach for prostate cancer patients to be detected outside of hospitals and laboratories.

This invention discloses a method for diagnosing prostate cancer using exosome surface proteomics, aiming to address the technical problems of insufficient specificity in existing prostate-specific antigen (PSA) detection and the inability of conventional exosome analysis techniques to simultaneously achieve source specificity and proteome coverage. The method includes: collecting and preprocessing biological fluid samples; using a dual-marker orthogonal barcoding system composed of DNA aptamer probes targeting CD63 protein and prostate-specific membrane antigen, respectively, to specifically capture and enrich prostate cancer-derived exosomes; selectively labeling their surface glycoproteins, followed by cleavage and enzymatic digestion to enrich surface glycoprotein peptides; and finally, inputting the data into a diagnostic model trained based on machine learning to output diagnostic results. This invention, through the organic combination of source-specific capture and panoramic surface proteome analysis, significantly improves the specificity and sensitivity of diagnosis, providing an efficient solution for non-invasive and accurate diagnosis and invasiveness assessment of prostate cancer.

The present application relates to a kind of sensitive prostate specific antigen combined detection kit and its preparation method, belong to detection reagent preparation technical field, the kit includes reagent R1-R5, PSA complex calibration, labeled antibody diluent and concentrated cleaning fluid and enhancing fluid, R1 contain buffer and biotin labeled first ACT antibody, R2 contain buffer and coupled SA protein magnetic microsphere, R3 contain biotin labeled tPSA antibody and biotin labeled second ACT antibody, R4 contain europium labeled fPSA antibody, R5 contain samarium labeled PSA- ACT antibody. Immunoreaction in the present application occurs in liquid-liquid phase reaction system, significantly reduce the adverse effects of steric hindrance on immunoreaction, further improve detection sensitivity, and the SA magnetic microsphere used can be used as general component for other kits, simplify production process, facilitate industrial production.

The present invention relates to a lentiviral vector comprising a nucleic acid sequence encoding at least one antigen sequence selected from the group consisting of human prostatic acid phosphatase, human prostate specific antigen, human prostate-specific membrane antigen, human prostate stem cell antigen, human six-transmembrane epithelial antigen of the prostate-1 and fragments thereof. It further relates to lentiviral vector particles, isolated cells or pharmaceutical compositions comprising a lentiviral vector according to the invention. The invention further provides a combinatory treatment comprising at least one lentiviral vector, lentiviral vector particle, isolated cell or pharmaceutical composition according to the invention, and at least one anticancer agent or treatment and / or at least one immunotherapy agent or treatment. Finally, the invention provides any of the above for use in the treatment and / or prevention of prostate cancers, in particular of metastatic prostate cancers, more particularly of metastatic castration-resistant prostate cancers.

The present invention relates to cancer vaccines and methods of treatment using the same. Disclosed is a vaccine composition, the present invention relates to a composition comprising one or more nucleic acids encoding one or more amino acid sequences selected from the group consisting of a tyrosinase, a tyrosinase-associated protein 1, a tyrosinase-associated protein 2, a melanoma-associated antigen 4 protein, a growth hormone releasing hormone, a MART-1 / melan-A antigen, a cancerous testis antigen NY-ESO-1, a cancerous testis antigen NY-ESO-2, the amino acid sequences of the antigen, the Vilms tumor 1 and the human telomerase reverse transcriptase are preferentially expressed in the melanoma. The vaccine compositions may further comprise nucleic acids encoding one or more other antigens, including prostate-specific antigens. Also disclosed are methods of preventing or treating cancer in a subject in need thereof, comprising administering to the subject a vaccine composition comprising a specific amount of cancer antigens to treat or prevent a specific cancer.

The present application relates to a kind of monoclonal antibody that can identify human PSA antigen, secreting cell strain, its preparation method and its use in immunodetection.The above technical scheme selects the amino acid of 31-124 of PSA protein as antigen peptide, is codon optimized, becomes the gene fragment suitable for expression in escherichia coli BL21, and finally the recombinant protein includes TRX protein label, PSA protein fragment and histidine protein label.The recombinant protein is immunized to mouse, is fused by cell, screening and subcloning, obtains the mouse hybridoma cell strain 16F1 of high-efficiency secreted anti-PSA protein monoclonal antibody and the anti-PSA protein monoclonal antibody secreted by the cell strain.The antibody obtained in the present application has high specificity, sensitivity, and can specifically recognize the cell expressing PSA protein, is suitable for immunological detection, especially immunohistochemical detection.

An assay system and method are provided. The system includes an assay zone including a binding ligand immobilized therein, the binding ligand selected from the group consisting of a binding ligand that binds free prostate specific antigen (fPSA), a binding ligand that binds intact prostate specific antigen (iPSA), a binding ligand that binds total prostate specific antigen (tPSA), and a binding ligand that binds human kallikrein 2 (hK2); at least one detector that detects the presence of an analyte in a sample from the assay zone, the analyte selected from the group consisting of tPSA, fPSA, iPSA, and hK2; and a processor programmed to: scale a plurality of variables by different coefficient values to produce scaled variables, the plurality of variables including age and at least two variables selected from the group consisting of fPSA, iPSA, and tPSA having values included in information received from the detector; sum the values of the scaled variables to produce a probability of a prostate cancer related event for the person; and output an indication of the probability of the prostate cancer related event.

The application provides a cancer risk degree discrimination method and system, and relates to the technical field of prostate cancer, which comprises the following steps: obtaining personal information of a screening object and a prostate specific antigen examination result of the screening object; determining a risk value of the antigen examination of the screening object based on the personal information of the screening object and the prostate specific antigen examination result of the screening object; if the risk value of the antigen examination of the screening object is greater than a preset threshold value, obtaining a prostate magnetic resonance scan image of the screening object; constructing a graph structure; determining prostate cancer analysis information by processing the graph structure based on a graph convolution network; generating a prostate cancer simulation growth video by using a generative adversarial network based on the prostate magnetic resonance scan image of the screening object and the prostate cancer analysis information; and determining the risk degree of the prostate cancer based on the prostate cancer simulation growth video, so that the risk of the occurrence of the prostate cancer can be accurately evaluated.

The present disclosure provides isolated peptides derived from prostate-specific antigen, peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treatment or prevention of prostate cancer. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treatment or prevention of prostate cancer.